Ono Pharmaceutical (OPHLF) Expected to Announce Quarterly Earnings on Friday

Ono Pharmaceutical (OTCMKTS:OPHLF) is expected to be posting its resultson Friday, July 31st. Analysts expect the company to post earnings of $0.25 per share and revenue of $679.8910 million for the quarter.

Ono Pharmaceutical Price Performance

Ono Pharmaceutical stock opened at $13.38 on Friday. The business’s 50 day simple moving average is $14.32 and its 200 day simple moving average is $14.73. Ono Pharmaceutical has a 12 month low of $10.27 and a 12 month high of $18.67. The company has a market cap of $6.29 billion, a price-to-earnings ratio of 13.52 and a beta of 0.34. The company has a current ratio of 3.02, a quick ratio of 2.56 and a debt-to-equity ratio of 0.10.

Analysts Set New Price Targets

Separately, Zacks Research raised shares of Ono Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Strong Buy”.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.